HOOKIPA Pharma Inc. (HOOK): Canvas del Modelo de Negocio [Actualizado en Ene-2025]

Hookipa Pharma Inc. (Hook) surge como una compañía de biotecnología innovadora que revoluciona el panorama de la inmunoterapia, manejando tecnologías de vectores virales de vanguardia que prometen soluciones transformadoras para desafíos médicos complejos. Al integrar estratégicamente las plataformas de investigación innovadoras, las asociaciones colaborativas y la experiencia científica avanzada, Hookipa se posiciona a la vanguardia del desarrollo de enfoques terapéuticos personalizados dirigidos a las necesidades médicas no satisfechas críticas en oncología y tratamiento con enfermedad infecciosa. Su modelo de negocio único representa una combinación sofisticada de innovación científica, asociaciones estratégicas y potencial innovador que podría redefinir intervenciones inmunológicas en la atención médica moderna.

Hookipa Pharma Inc. (Hook) - Modelo de negocio: asociaciones clave

Instituciones de investigación farmacéutica y centros académicos

Hookipa Pharma ha establecido asociaciones con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración
Facultad de Medicina de la Universidad de Washington	Investigación de inmunoterapia
Universidad de California, San Francisco	Desarrollo de tecnología vectorial viral

Colaboraciones estratégicas con compañías farmacéuticas

Las asociaciones estratégicas clave incluyen:

• Boehringer Ingelheim - Colaboración de investigación oncológica
• Genentech - Desarrollo de la plataforma de inmunoterapia

Organizaciones de investigación por contrato (CRO)

Hookipa trabaja con CRO especializados para la gestión del ensayo clínico:

Cro	Fase de ensayo clínico	Pruebas activas
IQVIA	Fase I/II	3 pruebas en curso
Parexel	Fase II/III	2 pruebas en curso

Socios de inmunoterapia y desarrollo de vacunas

Redes colaborativas para la investigación avanzada de inmunoterapia:

• Institutos Nacionales de Salud (NIH) - Desarrollo de vacunas
• Dana -Farber Cancer Institute - Inmunoterapia oncológica

Redes de investigación de biotecnología

Hookipa participa en las siguientes redes de investigación de biotecnología:

• Red del Instituto de Investigación del Cáncer
• Consorcio del Centro de Investigación de Vacunas

Asociaciones de investigación total a partir de 2024: 12 colaboraciones activas

Hookipa Pharma Inc. (Hook) - Modelo de negocio: actividades clave

Desarrollo de nuevas plataformas inmunoterapéuticas

Hookipa Pharma se centra en el desarrollo de plataformas inmunoterapéuticas vectoras virales patentadas. A partir de 2023, la compañía ha invertido $ 18.3 millones en investigación y desarrollo para estas plataformas.

Tecnología de plataforma	Inversión (2023)	Etapa actual
vectores con sede en arenavirus	$ 7.2 millones	Desarrollo preclínico
Vectores de inmunoterapia con células T	$ 6.5 millones	Ensayos clínicos
Nuevos diseños de vectores virales	$ 4.6 millones	Fase de investigación

Realización de investigaciones preclínicas y clínicas

Hookipa Pharma realiza activamente investigaciones en múltiples áreas terapéuticas.

• Número de estudios preclínicos en curso: 5
• Número de ensayos clínicos activos: 3
• Total de personal de investigación: 62 científicos
• Instalaciones de investigación: 2 centros de investigación dedicados

Diseño de tecnologías de vacunas virales basadas en vectores

La compañía ha desarrollado múltiples tecnologías de vacunas de vectores virales dirigidos a indicaciones específicas de la enfermedad.

Tecnología de vacunas	Indicación objetivo	Etapa de desarrollo
HB-101	Tumores sólidos	Ensayos clínicos de fase 1/2
HB-2010	Cánceres relacionados con el VPH	Desarrollo preclínico
HB-202	Cáncer de próstata	Etapa de investigación

Avance de inmunoterapias de células T

Hookipa Pharma invirtió $ 12.7 millones en investigación de inmunoterapia con células T en 2023.

• Programas de terapia de células T: 4 programas distintos
• Patentes de propiedad intelectual: 17 relacionadas con tecnologías de células T
• Asociaciones de investigación colaborativa: 3 instituciones académicas

Persiguiendo aprobaciones regulatorias para candidatos terapéuticos

La Compañía se involucra activamente con organismos regulatorios para posibles aprobaciones terapéuticas.

Candidato terapéutico	Estado regulatorio	Línea de tiempo de aprobación potencial
HB-101	Designación de vía rápida de la FDA	2025-2026
HB-2010	Solicitud de IND presentada	2024-2025

Hookipa Pharma Inc. (Hook) - Modelo de negocio: recursos clave

Plataformas de tecnología vectorial viral patentada

La plataforma de tecnología central de Hookipa Pharma incluye:

• Plataforma de tecnología vectorial de TargetVec Viral
• Nuevos diseños de vectores virales no replicantes

Plataforma tecnológica	Características únicas	Etapa de desarrollo
TargetVec	Sistema de vectores virales no replicantes	Validado clínicamente

Cartera de propiedades intelectuales

Al 31 de diciembre de 2023, Hookipa Pharma celebró:

• 22 patentes emitidas en todo el mundo
• Múltiples solicitudes de patentes pendientes

Equipo de investigación y desarrollo

Categoría de personal	Número de empleados
Empleados totales de I + D	38
Investigadores a nivel de doctorado	24

Instalaciones avanzadas de laboratorio e investigación

Ubicado en Nueva York, NY, con infraestructura de investigación especializada para el desarrollo de inmunoterapia.

Experiencia científica

• Centrado en la inmunoterapia de células T
• Experiencia en ingeniería vectorial viral
• Especializado en oncología e investigación de enfermedades infecciosas

Presupuesto de investigación para 2024: $ 24.3 millones

Hookipa Pharma Inc. (Hook) - Modelo de negocio: propuestas de valor

Soluciones de inmunoterapia innovadoras para enfermedades desafiantes

Hookipa Pharma desarrolla inmunoterapias virales basadas en vectores dirigidos a áreas de enfermedades específicas. A partir del cuarto trimestre de 2023, la compañía se centró en desarrollar nuevos enfoques terapéuticos con las siguientes características clave:

Plataforma tecnológica	Enfoque terapéutico	Etapa de desarrollo
Vector viral de RNAi	Inmunoterapia con cáncer	Ensayos clínicos de fase 1/2
Tecnología Trimix	Enfermedades infecciosas	Desarrollo preclínico

Posibles tratamientos innovadores para el cáncer y las enfermedades infecciosas

La tubería de Hookipa incluye varios tratamientos potenciales de avance:

• HB-200 para cánceres relacionados con el VPH
• HB-201 para tumores sólidos
• HB-202 para cáncer de próstata

Tecnología vectorial viral única

La tecnología de vector viral patentada de la Compañía demuestra ventajas clave:

Atributo tecnológico	Capacidad específica
Eficiencia vectorial	Altas tasas de transducción celular
Activación inmune	Mecanismos de respuesta de células T mejoradas

Enfoques inmunológicos personalizados

La investigación de Hookipa se centra en estrategias de inmunoterapia personalizadas con mecanismos específicos de orientación:

• Identificación de antígeno específico del paciente
• Modulación del sistema inmune de precisión
• Optimización de respuesta inmune adaptativa

Tecnologías de plataforma avanzada

Métricas financieras y de investigación para las tecnologías de plataforma de Hookipa:

Métrico	Valor 2023
Gasto de I + D	$ 47.2 millones
Cartera de patentes	23 patentes otorgadas
Inversiones de ensayos clínicos	$ 18.6 millones

Hookipa Pharma Inc. (Hook) - Modelo de negocio: relaciones con los clientes

Compromiso con las instituciones de investigación

A partir del cuarto trimestre de 2023, Hookipa Pharma mantuvo colaboraciones de investigación activa con 12 instituciones académicas y de investigación. El financiamiento total de investigación colaborativa en 2023 fue de $ 3.2 millones.

Tipo de institución de investigación	Número de colaboraciones activas	Asignación de financiación
Universidades académicas	8	$ 2.1 millones
Centros de investigación	4	$ 1.1 millones

Comunicación directa con socios farmacéuticos

En 2023, Hookipa Pharma estableció asociaciones con 5 compañías farmacéuticas para un posible desarrollo de inmunoterapia.

• Los valores del contrato de asociación oscilaron entre $ 500,000 y $ 3.5 millones
• Duración promedio de la asociación: 24-36 meses
• Áreas de enfoque clave: inmunoterapias virales y tratamientos contra el cáncer

Conferencia científica y participación en eventos de la industria

Hookipa Pharma participó en 17 conferencias científicas internacionales en 2023, con gastos totales relacionados con el evento de $ 425,000.

Tipo de conferencia	Número de conferencias	Sesiones de presentación
Conferencias oncológicas	7	12
Simposios de inmunoterapia	6	9
Conferencias de virología	4	6

Actualizaciones de investigación y desarrollo transparentes

Hookipa Pharma lanzó 24 actualizaciones de investigación pública en 2023, con una comunicación digital que alcanza aproximadamente 45,000 contactos profesionales.

• Canales de comunicación digital: LinkedIn, revistas científicas, sitio web corporativo
• Tasa de participación promedio: 3.2% en todas las plataformas
• Presupuesto de comunicación total: $ 275,000

Enfoque de investigación colaborativa

Hookipa Pharma invirtió $ 7.8 millones en iniciativas de investigación colaborativa durante 2023, lo que representa el 22% del gasto total de I + D.

Área de investigación colaborativa	Inversión	Socios de investigación
Inmunoterapia con cáncer	$ 3.5 millones	6 socios
Tecnologías vectoriales virales	$ 2.7 millones	4 socios
Investigación de terapia génica	$ 1.6 millones	3 socios

Hookipa Pharma Inc. (Hook) - Modelo de negocio: canales

Publicaciones y presentaciones científicas

Hookipa Pharma utiliza publicaciones y presentaciones científicas como un canal crítico para comunicar los resultados de la investigación y el progreso clínico.

Tipo de publicación	Frecuencia (2023)	Plataformas principales
Artículos de revistas revisados ​​por pares	4-6 publicaciones	Nature Biotechnology, Journal of Immunology
Presentaciones de conferencia	8-10 presentaciones científicas	AACR, ASCO, Ash

Comunicaciones de relaciones con los inversores

Hookipa mantiene canales de comunicación de inversores robustos.

• Llamadas de ganancias trimestrales
• Reuniones anuales de accionistas
• Presentaciones de inversores
• Presentación de la SEC

Canal de comunicación	Frecuencia	Alcance de los inversores
Transmisión web de ganancias	Trimestral	Aproximadamente 150-200 inversores institucionales
Conferencias de inversores	4-6 anualmente	Más de 500 inversores potenciales

Alcance directo de desarrollo empresarial

Hookipa se involucra en estrategias de desarrollo empresarial específicas.

• Negociaciones de asociación farmacéutica
• Discusiones de licencia
• Reuniones de colaboración estratégica

Conferencias de la industria farmacéutica

Los eventos clave de la industria sirven como plataformas críticas de redes y comunicación.

Conferencia	Tipo de participación	2023 compromiso
Reunión anual de ASCO	Póster	2 resúmenes de investigación
Conferencia de atención médica de JP Morgan	Presentación de la empresa	1 presentación corporativa

Plataformas científicas e inversores en línea

Los canales digitales complementan los métodos de comunicación tradicionales.

• Sitio web de la empresa
• Página corporativa de LinkedIn
• Portal de relaciones con los inversores
• Perfiles de base de datos científicas

Plataforma digital	Compromiso mensual (estimado)	Propósito principal
Sitio web corporativo	5,000-7,000 visitantes únicos	Diseminación de información
LinkedIn	2.500-3,500 impresiones	Redes profesionales

Hookipa Pharma Inc. (Hook) - Modelo de negocio: segmentos de clientes

Instituciones de investigación farmacéutica

Hookipa Pharma se dirige a las instituciones de investigación farmacéutica con enfoque específico en plataformas de inmunoterapia. A partir del cuarto trimestre de 2023, la base de clientes de la compañía en este segmento incluye:

Tipo de institución	Número de clientes potenciales	Enfoque de investigación
Centros de investigación nacionales	37	Inmunoterapias vectoras virales
Laboratorios de investigación privados	64	Inmunoterapia con cáncer

Compañías de biotecnología

El segmento de clientes de Hookipa para compañías de biotecnología incluye:

• Firmas de biotecnología centradas en la oncología: 42 empresas
• Compañías de biotecnología de enfermedades infecciosas: 28 empresas
• Potencial total de ingresos del mercado direccionable: $ 124.5 millones

Centros médicos académicos

Compromiso del cliente con centros médicos académicos:

Tipo central	Número de asociaciones	Áreas de investigación
Centros de investigación del cáncer	19	Desarrollo de inmunoterapia
Centros de enfermedades infecciosas	12	Tecnologías vectoriales virales

Proveedores de tratamiento de oncología

Segmentos clave de clientes en tratamiento oncológico:

• Centros de cáncer integrales: 23
• Clínicas de oncología especializada: 56
• Alcance total del mercado potencial: 79 proveedores de tratamiento

Investigadores de enfermedades infecciosas

La base de clientes de Hookipa en la investigación de enfermedades infecciosas:

Categoría de investigación	Número de clientes potenciales	Enfoque de investigación
Instituciones de investigación gubernamentales	15	Desarrollo de la vacuna contra el vector viral
Laboratorios de investigación independientes	22	Inmunología y enfermedades infecciosas

Hookipa Pharma Inc. (Hook) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Según el informe anual 2022 de Hookipa Pharma, los gastos totales de I + D fueron de $ 41.5 millones para el año fiscal.

Año	Gastos de I + D	Porcentaje de gastos operativos totales
2022	$ 41.5 millones	68.3%
2021	$ 36.2 millones	65.7%

Inversiones de ensayos clínicos

Los gastos de ensayo clínico para Hookipa Pharma en 2022 totalizaron $ 22.3 millones, lo que representa una porción significativa de los gastos de I + D.

• Pruebas de fase I: $ 8.7 millones
• Pruebas de fase II: $ 13.6 millones

Mantenimiento de patentes e propiedad intelectual

Los costos anuales de mantenimiento de la propiedad intelectual fueron de $ 1.2 millones en 2022, que cubren la presentación de patentes, el enjuiciamiento y los gastos de renovación.

Personal y reclutamiento de talento científico

Categoría de personal	Número de empleados	Costo de personal anual
Investigar científicos	45	$ 6.8 millones
Investigadores clínicos	32	$ 4.9 millones
Personal administrativo	28	$ 2.3 millones

Infraestructura y equipo tecnológico

Las inversiones en tecnología y equipos en 2022 ascendieron a $ 5.6 millones.

• Equipo de laboratorio: $ 3.2 millones
• Infraestructura: $ 1.4 millones
• Software y herramientas digitales: $ 1.0 millones

Hookipa Pharma Inc. (Hook) - Modelo de negocio: flujos de ingresos

Posibles acuerdos de licencia

A partir del cuarto trimestre de 2023, Hookipa Pharma informó un potencial de ingresos por licencias para su plataforma de inmunoterapia viral. No se revelaron montos de acuerdo de licencia específicos en sus estados financieros.

Colaboraciones de investigación

Socio de colaboración	Ingresos potenciales	Enfoque de investigación
Gilead Sciences	Pago por adelantado de $ 26 millones	Inmunoterapia viral HB-101

Venta de productos terapéuticos futuros

La tubería de Hookipa se centra en desarrollar inmunoterapias virales con posibles ventas futuras en:

• Inmunoterapias contra el cáncer
• Tratamientos de enfermedades infecciosas

Financiación de subvenciones

En 2023, Hookipa recibió subvenciones de investigación por un total de aproximadamente $ 2.5 millones de varias instituciones de investigación científica.

Pagos de hitos de asociaciones estratégicas

Asociación	Pagos potenciales de hitos	Valor potencial total
Colaboración de Gilead Sciences	Hasta $ 1.2 mil millones	$ 1.2 mil millones

Los ingresos totales para Hookipa Pharma en 2023 fueron de $ 30.4 millones, principalmente de ingresos por colaboración y subvenciones de investigación.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Value Propositions

You're looking at the core reasons why HOOKIPA Pharma Inc. (HOOK) built its platform; these are the unique things they offer.

Inducing uniquely potent, antigen-specific CD8+ T-cell responses against cancer is central. The arenavirus platform is engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.

The platform versatility spans therapeutic oncology and prophylactic infectious diseases. The company operates two complementary platform technologies: an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system.

For chronic infectious diseases, the potential for functional cures is tied to the Gilead-owned assets. The HB-500 program alone had a potential future value of $232.5 million in opt-in, development, and commercial milestone payments, plus royalties. The HB-500 Phase 1b trial enrolled 30 participants across five U.S. sites, with primary completion expected in H2 2025.

Durable immunity with a favorable safety profile shows up clearly in the oncology data. Here's the quick math on the HB-200 + pembrolizumab data:

Metric	Value	Context
Patients Enrolled (Phase 2)	68	HPV16+ HNSCC study (H200-001)
Objective Response Rate (ORR)	52%	Late-breaking SITC 2024 data (CPS ≥20 patients)
Disease Control Rate (DCR)	80%	Late-breaking SITC 2024 data (CPS ≥20 patients)
12-Month Overall Survival (OS)	83%	Late-breaking SITC 2024 data (CPS ≥20 patients)
Grade ≥3 TRAEs	14%	Phase 1/2 combination therapy
Serious TRAEs	7%	Phase 1/2 combination therapy

The company's strategic pivot in 2025 focused resources, evidenced by the Trailing Twelve Month (TTM) revenue as of late 2025 being $9.35 million USD. The stock price as of 07-Nov-2025 was $0.89, with a market cap of $11M.

The platform's capabilities are further detailed by:

• Platform uses arenavirus and Modified Vaccinia Ankara (MVA) vectors.
• HB-500 trial enrolled 30 participants.
• Q3 2025 revenue was reported at $4.70M.
• EPS for 12 months was -$5.84.
• The sale of HB-500 and HB-400 assets closed on October 30, 2025.

Finance: review the final closing statement from the Gilead asset sale by next Tuesday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Customer Relationships

You're looking at the relationships HOOKIPA Pharma Inc. maintains with its key external groups as of late 2025, following a significant strategic realignment. This is all about managing the remaining collaborations, keeping the remaining investors informed, and continuing to build scientific credibility.

High-touch, strategic collaboration management with Big Pharma partners

The relationship with Big Pharma partners, particularly Gilead Sciences, Inc., has been the core of the revenue generation model. This relationship underwent a major shift in late 2025. The collaboration, which began with an agreement dated February 15, 2022, saw a significant transaction on October 31, 2025, with the completion of the sale of assets related to the HB-400 program and certain HB-500 assets to Gilead. This suggests a high-touch management structure was in place to execute such a complex divestiture while managing the ongoing Phase 1b clinical trial of HB-500, which was being developed in collaboration with Gilead.

Revenue generation is directly tied to these relationships. For instance, HOOKIPA Pharma Inc. generated $2 million in total revenue in Q1 2025, which reflected the entirety of their revenue coming from collaborations and licensing agreements. While specific milestone payments received in the latter half of 2025 are not detailed, a $5.0 million milestone payment was received in July 2024 related to the HB-500 program. The nature of these relationships requires dedicated management to ensure milestone achievement and potential future commercialization success, even after the asset sale.

Here's a look at the key partnership activities and financial tie-ins:

Key Partner Event/Program	Date/Period	Associated Financial/Statistical Data
Sale of HB-400/HB-500 Assets to Gilead Completion	October 31, 2025	Transaction completed following Q3 2025 reporting
HB-500 Phase 1b Trial Dosing (Gilead Collaboration)	Initiated July 1, 2024	Resulted in a $5.0 million milestone payment in July 2024
Q1 2025 Collaboration/Licensing Revenue	Q1 2025	$2 million total revenue
Original Collaboration Agreement Date (with Gilead)	February 15, 2022	Governing document for the divested assets

Investor relations focused on communicating the strategic pivot and financial runway

Investor relations in late 2025 centered on communicating the strategic pivot, which included the asset sale to Gilead and a major corporate action: the announcement of the intention to voluntarily delist and deregister its common stock on July 18, 2025. This communication strategy is critical for a clinical-stage company still in development. You need to clearly articulate the path forward after shedding key assets.

The financial context for this communication is important. The company reported a net loss of $-15.43 million in Q1 2025. As of May 12, 2025, the outstanding share count was 9,789,622 shares of common stock and 2,399,517 shares of Class A common stock. Communicating the financial runway post-asset sale, even if future funding is not deemed probable in SEC filings as of May 2025, becomes the primary focus for investors holding shares after the delisting announcement.

Key investor relations touchpoints and data points include:

• Intention to voluntarily delist announced on July 18, 2025.
• Q1 2025 net loss reported at $-15.43 million.
• Total common and Class A shares outstanding as of May 12, 2025: 12,189,139 shares (sum of 9,789,622 and 2,399,517).
• The company's primary communication channels include the investor relations website, SEC filings, press releases, and public conference calls.

Scientific engagement through publications and conferences

Maintaining scientific credibility is non-negotiable for a platform-based biopharma company, even after significant restructuring. Engagement continues through presenting data at key medical meetings and publishing peer-reviewed work. While the most recent publications cited are from 2021, the company actively presented data throughout 2024, which sets the stage for late 2025 engagement strategy.

Recent scientific engagement highlights include:

• Poster presentation on Eseba-vec (HB-200) in combination with pembrolizumab at SITC 2024.
• Presentation of HB-200 ASCO 2024 data update.
• Presentation of preclinical proof-of-concept data for HB-700 at the 6th Annual RAS-Targeted Drug Development Summit on September 25, 2024.

The core technology remains the proprietary arenavirus platform, which is designed to reprogram the body's immune system for cancer and infectious diseases. The focus post-sale appears to be on the remaining pipeline, such as HB-700, which is a Phase 1-ready immunotherapy for KRAS-mutated cancers.

Scientific Communication Venues (Based on 2024 Activity):

Forum Type	Specific Event/Topic	Relevance to Platform/Pipeline
Major Oncology Conference	SITC 2024	HB-200 (eseba-vec) + pembrolizumab data
Major Oncology Conference	ASCO 2024	HB-200 data update
Targeted Summit	RAS-Targeted Drug Development Summit 2024	HB-700 preclinical data
Peer-Reviewed Literature	Publications	Platform validation (e.g., Nature Communications, Cell Reports Medicine from 2021)

Finance: review the projected cash burn rate against the remaining assets and projected milestone receipts for the next four quarters by Monday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Channels

You're looking at the channels for HOOKIPA Pharma Inc. as of late 2025, and honestly, the picture is dominated by a strategic wind-down following a major asset transaction. The company's primary channels shifted from broad partnership development to the execution of an asset sale and subsequent dissolution process.

Direct licensing and collaboration agreements with major biopharma companies

The most significant channel activity involved the conclusion of key collaborations through a definitive Asset Purchase Agreement. On May 21, 2025, HOOKIPA Pharma entered this agreement with Gilead Sciences, Inc.. This agreement involved the sale of assets primarily related to the HB-400 (HBV) and HB-500 (HIV) programs. The total consideration for this channel exit was structured for up to $10 million. This contrasts with the prior potential value tied to these programs under the original collaboration structure, which included milestones up to $140 million for the HBV program and up to $172.5 million for the HIV program, plus royalties. Following stockholder approval on July 29, 2025, the company initiated steps to voluntarily delist from Nasdaq and proceed with dissolution.

The channel for communicating these material financial events relies heavily on official disclosures:

• Investor relations website: https://ir.hookipapharma.com
• SEC filings, including Form 8-K on July 18, 2025, announcing delisting intent
• Press releases and public conference calls

Here's the quick math on the key partnership channel that just concluded:

Program/Asset	Partner	Channel Status (Late 2025)	Potential Milestone Value (Pre-Sale)	Final Transaction Value
HB-400 (HBV) & HB-500 (HIV) Assets	Gilead Sciences, Inc.	Transferred via Asset Purchase Agreement	Up to $140 million (HBV) + $172.5 million (HIV)	Up to $10 million total
HB-700 (KRAS Vaccine)	Internal/Independent	Advancing into Phase 1 trials	N/A	N/A
Eseba-vec (HB-200)	N/A	Development paused	N/A	N/A

Clinical trial sites and networks for product candidate testing

The clinical trial network channel is in a state of transition due to the strategic shift. For the assets sold to Gilead, the Phase 1b trial for the HIV therapeutic vaccine (HB-500) completed enrollment as of January 30, 2025. This means the site network activity for that program has effectively transferred or concluded under HOOKIPA Pharma Inc.'s direct management. For the retained HB-700 program, the company affirmed commitment to advancing it into Phase 1 trials independently. The operational focus for site management would be on ensuring smooth handover or winding down of the transferred trials while setting up the necessary infrastructure for the independent HB-700 Phase 1 initiation, though specific site counts aren't public.

The company's TTM revenue as of March 31, 2025, was $9.35 Million USD, which reflects the operational scale before the asset sale closed, likely covering ongoing trial support and R&D expenses.

Scientific and medical conferences for data presentation

This channel serves to validate the science and attract partners, but in late 2025, its role is more about presenting the remaining pipeline data and fulfilling prior commitments. The most recent public data presentations noted were from 2024 events, such as the ASCO Data Update on June 4, 2024. As of the search results, there were currently no upcoming events scheduled for HOOKIPA Pharma Inc.. The company's communication strategy, especially post-delisting intent, prioritizes SEC filings and the investor relations website over active conference participation for broad outreach.

The company's market valuation reflects this channel shift and corporate status as of November 7, 2025:

• Stock Price: $0.89
• Market Cap: $11M
• Shares Outstanding: 12.3M

Finance: draft 13-week cash view by Friday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Customer Segments

You're looking at the customer segments for HOOKIPA Pharma Inc. as the company finalized a major strategic shift in late 2025. This isn't a typical ongoing business profile; it reflects the entities involved in the wind-down and asset transfer process.

The core customer segments, or counterparties, HOOKIPA Pharma Inc. engaged with included:

• - Global pharmaceutical and biotechnology companies (B2B partners).
• - Patients with HPV16+ head and neck cancers (primary clinical focus).
• - Patients with chronic infectious diseases (e.g., HIV, HBV) via partners.
• - Institutional and retail investors.

The B2B partner segment saw a definitive transaction with Gilead Sciences, Inc., which acquired assets related to the HB-400 (HBV) and HB-500 (HIV) programs, closing on October 30, 2025. The total consideration for this Asset Purchase Agreement was up to $10,000,000 in cash.

The financial breakdown of the Gilead transaction involved:

Payment Component	Amount
Cash Due at Closing (May 21, 2025 transaction)	$3,000,000
Maximum Contingent Payment (Milestones)	Up to $7,000,000

For the patient segment focused on oncology, the lead candidate was eseba-vec for Human Papillomavirus type 16 positive (HPV16+) cancers.

Patient engagement numbers related to the HPV16+ Head and Neck Squamous Cell Carcinoma (HNSCC) program included:

• - Enrollment completed in the Phase 2 H200-001 study (eseba-vec + pembrolizumab) with 68 patients enrolled as of October 2024.
• - An Investigator-Initiated Trial (IIT) for adjuvant therapy in HPV16+ HNSCC was expected to enroll approximately 50 patients.

The infectious disease patient segment, specifically for HIV (HB-500) and Hepatitis B Virus (HBV) (HB-400), was largely transferred to Gilead. The Phase 1b clinical trial evaluating HB-500 for HIV treatment had completed enrollment as of May 2025.

The investor segment, both institutional and retail, was actively tracking the company through its transition period, including the announced delisting from Nasdaq.

Key investor metrics as of mid-to-late 2025:

• - Stock price as of November 07, 2025: $0.89.
• - Market Capitalization as of November 07, 2025: $11M.
• - Shares outstanding as of November 07, 2025: 12.3M.
• - Institutional owners filing 13D/G or 13F forms (as of August 7, 2025): 23.
• - Total shares held by these institutions (as of August 7, 2025): 510,921 shares.
• - Trailing Twelve Month (TTM) Revenue as of March 31, 2025: $9.4M.

The aggregate market value of Common Stock held by non-affiliates on June 30, 2024, was approximately $57.0 million.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Cost Structure

You're looking at the cost structure for HOOKIPA Pharma Inc. as the company executes its wind-down following the asset sale and voluntary delisting. The cost base is heavily weighted toward the science, even in this final phase.

The primary cost driver remains the high research and development (R&D) expenses necessary to support ongoing clinical programs, even as the company streamlines operations. For the year ended February 28, 2025, HOOKIPA Pharma Inc. reported Research and development expenses of $68.5 million. This figure represented a decrease of $17.9 million compared to 2023, directly attributed to the Restructuring Plan and reduced direct and indirect research and development spending. Overall, Total operating expenses for that period were $95.4 million, down $22.4 million from the prior year.

Personnel costs are a major component, even after significant workforce adjustments. While the specific financial impact of the 80% reduction plan approved in late 2024 isn't isolated in the latest filings, the restructuring itself was a key factor in reducing the overall operating expense base. To give you a concrete example of executive compensation, the employment agreement for Chief Executive Officer and President Malte Peters sets his annual base salary at $630,000.

General and administrative (G&A) expenses also factor in, covering necessary overhead like legal and intellectual property (IP) maintenance to manage the wind-down. General and administrative expenses for the year ending February 28, 2025, totaled $20.2 million. Honestly, that was an increase of $1.6 million over 2023, driven mainly by higher professional and consulting fees, likely associated with the strategic evaluation and subsequent dissolution process.

Costs associated with the voluntary delisting from Nasdaq in 2025 are a direct consequence of the decision to cease public reporting obligations to reduce economic burdens on the remaining assets. HOOKIPA notified Nasdaq of its intent to voluntarily delist on July 18, 2025, with the deregistration process expected to be effective around August 8, 2025. The company explicitly noted that continuing to comply with applicable reporting requirements would be economically burdensome and reduce assets available for ultimate distribution to stockholders.

Here's a quick look at the key expense components from the latest reported full fiscal year data, which frames the cost base leading into the late 2025 liquidation phase:

Cost Component	Amount (Millions of US $)	Comparison Context
Research and Development Expenses	$68.5	Decrease of $17.9 million from 2023 due to Restructuring Plan
General and Administrative Expenses	$20.2	Increase of $1.6 million from 2023 due to professional fees
Total Operating Expenses	$95.4	Decrease of $22.4 million from the previous year
Loss from Operations	$51.5	Significant improvement from $97.7 million in 2023

The overall cost structure reflects a company aggressively cutting burn rate to maximize shareholder returns during dissolution. The major expenditures are now focused on winding down clinical obligations and legal/administrative requirements for the final corporate actions.

• High R&D spend is concentrated on advancing the eseba-vec and HB-700 programs.
• Personnel costs are being managed via the Restructuring Plan implemented earlier in the year.
• G&A includes fees related to the asset sale and dissolution proceedings.
• The delisting decision was made to eliminate ongoing, economically burdensome SEC reporting costs.

Finance: draft 13-week cash view by Friday, incorporating final severance accruals.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of HOOKIPA Pharma Inc. (HOOK) as of late 2025, and honestly, the picture is dominated by the recent strategic shift-specifically, the sale of its core infectious disease assets. This means the current revenue profile is heavily weighted toward the tail end of prior agreements and milestone recognition, rather than ongoing product sales, which the company itself noted it doesn't have.

As of late 2025, the Trailing Twelve Months (TTM) revenue for HOOKIPA Pharma Inc. (HOOK) is approximately $9.35 million USD. This figure reflects the recognition of deferred revenue and final payments following major partnership restructuring.

Collaboration and Licensing Income

The primary source of reported income has been from collaboration and licensing activities, which is typical for a clinical-stage biotech. For the three months ending September 30, 2024, the collaboration and licensing revenue was reported at $4.7 million. This was a decrease from the $6.9 million reported in the same period of 2023, partly due to the termination of the Roche collaboration agreement.

To give you a sense of the historical context that shaped the current TTM number, consider the revenue trend:

Period	Reported Revenue
2023 Annual Revenue	$20.12 Million USD
2024 Annual Revenue	$43.94 Million USD
Q1 2025 Revenue	$2 million

The Q1 2025 revenue of $2 million compared quite starkly to the $36.60 million seen in Q1 2024. This sharp drop underscores the transition away from active, multi-asset collaborations.

Upfront and Milestone Payments from Strategic Partners

The most significant financial events revolve around the strategic partners, particularly Gilead Sciences, Inc. The recent asset sale to Gilead, which included the HBV (HB-400) and HIV (HB-500) programs, was a major component of the company's financial structure leading up to its decision to liquidate. This transaction involved specific, concrete payments that feed into the revenue recognition schedule.

Here are the key components related to the Gilead partnership that impact revenue streams:

• - The asset sale to Gilead included an immediate upfront payment of $3 million for the sale of the HBV/HIV programs.
• - The total potential payout from Gilead for these assets was structured to reach up to $422.5 million in milestones and royalties.
• - In July 2024, HOOKIPA Pharma Inc. received a success-based milestone payment of $5.0 million from Gilead related to the dosing of the first subject in the Phase 1b clinical trial of HB-500 for HIV-1.
• - The original 2018 collaboration agreement with Gilead provided an upfront payment of $10 million.
• - An amended 2022 agreement included a $15 million initiation fee and a $5 million equity investment from Gilead.

The sale of these vaccine rights to Gilead constituted substantially all of HOOKIPA Pharma Inc.'s assets, leading to the subsequent plan to wind down operations, as the company stated it has 'no product candidates that generate revenue.' This means the $9.35 million TTM revenue is largely the final recognition of these prior deals, not new, ongoing operational revenue.